Fig. 4: Alveolar fluid clearance improvements by protectin DX were partly dependent on ALX, cAMP, and the PI3K pathway in vivo. | Experimental & Molecular Medicine

Fig. 4: Alveolar fluid clearance improvements by protectin DX were partly dependent on ALX, cAMP, and the PI3K pathway in vivo.

From: Protectin DX increases alveolar fluid clearance in rats with lipopolysaccharide-induced acute lung injury

Fig. 4

Protectin DX (5 µg/kg) and BOC-2 (ALX receptor inhibitor, 600 ng/kg), LY294002 (PI3K inhibitor, 3 mg/kg), Rp-cAMP (5 mg/kg), Rp-cGMP (5.5 mg/kg) or H89 (10 mg/kg) were co-injected into the caudal veins of Sprague-Dawley rats 8 h after LPS (14 mg/kg) stimulation; then, intratracheal instillation of a 5% albumin solution containing Evans blue-labeled albumin (5 ml/kg) through a tracheostomy to the left lung was performed to measure alveolar fluid clearance (e), and right lung tissues were harvested to measure cAMP concentrations by using ELISA kits (a, b) and phosphorylated Akt (c) and Nedd4-2 (d) protein expression levels by western blotting. The data are presented as the mean ± SD. n = 8. PDX protectin DX. Alcohol was the solvent for protectin DX. **p < 0.01 versus the control group; ††p < 0.01 versus the LPS group; ‡p < 0.05, ‡‡p < 0.01 versus the LPS + PDX group

Back to article page